TABLE 1
FROM:
Patent expiries in the US statin market: Generics to slash market size by 80 per cent over the next ten years
Duncan Emerton
BACK TO ARTICLETable 1. The US statin monotherapy* market, 2005
| Brand | Generics | Marketing company | SUs 2005 (m) | Growth 2004–05 (%) | Sales 2005 (US$m) | Growth 2004–05 (%) |
|---|---|---|---|---|---|---|
| Lipitor | Atorvastatin | Pfizer | 3,200 | 2.7 | 8,064 | 8.5 |
| Zocor | Simvastatin | Merck & Co. | 1,566 | (7.7) | 4,206 | (4.7) |
| Pravachol | Pravastatin | BMS | 500 | (19.9) | 1,655 | (13.9) |
| Crestor | Rosuvastatin | AstraZeneca | 345 | 23.8 | 797 | 36.3 |
| Lescol | Fluvastatin | Novartis | 184 | (12.6) | 336 | (8.3) |
| Mevacor | Lovastatin | Merck & Co. | 3 | 39.3) | 8 | (36.4) |
| Total | 5,798 | (2.3) | 15,066 | 2.3 |
Does not include sales of combination therapies (eg Vytorin, Caduet)
BMS – Bristol Myers Squibb
Source: IMS MIDAS sales data, IMS Health, March 2006
